Voulez-vous consulter la version mobile de ce site ?

Biography

Alain Puisieux

Alain Puisieux

Following his Pharmacy internship in Paris (France), Alain Puisieux started a fellowship at the Massachussets General Hospital, Boston (United States, 1989-1991), to investigate the molecular mechanisms of hepatocarcinogenesis. He then joined the Cancer Centre Léon Bérard in Lyon (France), where he created the Molecular Oncology Laboratory in 1997. He was promoted Professor in Biochemistry and Cellular Biology at the Claude Bernard University in 1999. Alain Puisieux headed the U590 Inserm unit “Oncogenesis and tumoral progression” from 2003 to 2010. Currently, he is the Director of the Centre de Recherche en Cancérologie de Lyon (23 teams, 480 staff members). He is a member of the French National Academy of Medicine, of the French National Academy of Pharmacy and a former member of the Institut Universitaire de France. His scientific team focuses its work on the role of EMT-inducing transcription factors in cancer cell plasticity and intra-tumor heterogeneity.

Catherine Alix-Panabieres

Catherine Alix-Panabieres

Dr Catherine Alix-Panabières received her PhD degree in 1998 at the Institute of Virology, University Louis Pasteur, in Strasbourg in France. In 1999, she moved to Montpellier where she did a postdoctoral research in the Department of Immuno-Virology of the University Medical Centre of Montpellier, France. During this last decade, Dr Alix-Panabières has focused on optimizing new techniques of enrichment and detection of viable disseminating tumor cells in patients with solid tumors. She is the expert for the EPISPOT technology that is used to detect viable tumor cells in the peripheral blood and the bone marrow of patients with breast, prostate, colon, head & neck cancer and melanoma. In 2010, she achieved getting a permanent position at the Hospital and at the Faculty of Medicine of Montpellier (MCU-PH), a wonderful mixture of giving teaching lessons to medical students on Cancer Biology in combination of developing this field of tumor cell dissemination at the hospital for the cancer patients, leading strongly translational clinical research. As an associate professor, she recently became the new director of the Laboratory of Rare Human Circulating Cells (LCCRH) in the Department of Cell & Tissue Biopathology of tumors. In this unique platform LCCRH, they isolate, detect and characterize circulating tumor cells using combinations of the EPISPOT assay, the CellSearch® system (Menarini), the flow cytometry, the CellCollector (GILUPI), the molecular biology (AmpliSpeed device), the Parsortix system and the DEPArray (Silicon Biosystem). She has authored or co-authored >60 scientific publications in this field during the last years including 10 book chapters and she is part of big European projects: CTC-SCAN (Transcan project), CANCER-ID (IMI project) and European Liquid Biospy Academy (ELBA, Marie Curie project). After she got the Scientific Prize given by the Region Languedoc-Roussillon in 2008, it was a great honor for her to receive the Gallet et Breton Cancer Prize, the highest honor conferred by the French Academy of Medicine in November 2012 and, very recently, the 2017 AACR Award for the most cited scientific article in 2015 (Cayrefourcq et al. Cancer Res).

Christine Gilles

Christine Gilles

Christine Gilles received her PhD in Science in 1994 at the University of Liège in Belgium. Along the way, she gained increasing interest in Epithelial-to-Mesenchymal Transitions. She therefore joined the laboratory of Professor Rik Thompson at Georgetown University (Washington DC) for a 3 year post-doc to deepen her knowledge in this particular field. Coming back to her home University, she was given tenure as a Research Associate at the FNRS (Fonds National de la Recherche Scientifique, Belgium). In 2008, she was promoted to a Senior Research Associate position at the FNRS. She is today the principal investigator of an EMT-research team at the University of Liège deciphering mechanisms of EMT implicated in metastasis, and has (co-)authored 63 international peer-reviewed publications in the field. Most recently, she initiated a research axis that originally emphasized a role for EMT pathways in providing CTCs with coagulant properties, thereby facilitating early metastasis.

Daniel Hayes

Daniel Hayes

Daniel F. Hayes, MD, FASCO, FACP Dr. Daniel F. Hayes is the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, where he is the Stuart B. Padnos Professor of Breast Cancer Research. Dr. Hayes received bachelor’s, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Health Science Center/Parkland Memorial Hospital from 1979 to 1982. After a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI) from 1982 to 1985, he remained on faculty and was the Medical Director of the Breast Evaluation Center at DFCI from 19912-1996. He subsequently became the Director of the Breast Cancer Program at Georgetown University’s Lombardi Cancer Center from 1996 to 2001, when he moved to the University of Michigan.

Hugh Fan

Hugh Fan

Dr. Z. Hugh Fan is the George N. Sandor Faculty Fellow and a Professor of the Department of Mechanical and Aerospace Engineering, J. Crayton Pruitt Family Department of Biomedical Engineering, and Department of Chemistry in the University of Florida (UF), USA. Dr. Fan’s research interests include microfluidics, BioMEMS, sensors, and cancer diagnosis and prognosis. He has authored >80 journal articles that have been cited for more than 5000 times, and edited a book entitled Circulating Tumor Cells: Isolation and Analysis (by Wiley). Dr. Fan’s research efforts have been recognized by Fraunhofer-Bessel Award from Alexander von Humboldt Foundation (Germany), E.T.S. Walton Award from Science Foundation Ireland, and Career Award from National Institute of Health (USA).  He is a Fellow of the American Association for the Advancement of Science (AAAS), an editor of Microsystems & Nanoengineering (Nature Publishing Group), and an editorial board member of Scientific Reports.

Jean Paul Thiery

Jean Paul Thiery

Jean Paul Thiery is Research Director Emeritus at the Comprehensive Cancer Center, Villejuif, France and a Visiting Professor at the School of Medicine of National University of Singapore (NUS). He was until June 2015, Professor and Head of the Biochemistry Department, School of Medicine, NUS. His influential works include pioneering studies in cell adhesion and migration in early embryogenesis and in elucidating the roles of growth factors and adhesion signaling molecules in Epithelial-Mesenchymal Transitions (EMT). Jean Paul Thiery is credited to be the first to propose that EMT controls carcinoma cell invasion and dissemination.

Joan Massagué

Joan Massagué

Joan Massagué, Ph.D. Joan Massagué (Barcelona, 1953) received a B.S. degree in Pharmacy in 1975 and a Ph.D. degree in Biochemistry in 1978, from the University of Barcelona, Spain. After postdoctoral training at Brown University, he joined the faculty at the University of Massachusetts Medical School in 1982. In 1989 he was appointed Alfred P. Sloan Chair at Memorial Sloan Kettering Cancer Center, New York. He served as Chair of the Cell Biology Program (1989-2003) and the Cancer Biology and Genetics Program (2003-2013). He was an Investigator of the Howard Hughes Medical Institute starting from 1980 until he assumed his current position as Director of the Sloan Kettering Institute in 2014. Dr. Massagué is a world leader in the signaling pathways and transcriptional programs that determine cell behavior and cancer metastasis. He identified the TGF-beta receptors, elucidated the TGF-beta signal transduction pathway, and defined the central concept of how this pathway controls cell fate. He provided a direct explanation for how these external signals control cell proliferation through cell cycle inhibitors, cell differentiation through chromatin regulators, and tumor suppression through cancer cell death. These mechanisms proved to be crucial in embryonic development, and their disruption causes congenital disorders and cancer. Building on this work, Dr. Massagué identified molecular mechanisms for metastatic latency and metastatic colonization of distant organs, thus illuminating the basis for metastasis as the overwhelming cause of cancer mortality, and opening new avenues for treatment. He has published over 300 papers and ranks as one of the most highly cited investigators in biomedical sciences. Dr. Massagué is an elected member of the U.S. National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, the European Molecular Biology Organization, and the Spanish Royal Academies of Medicine and of Pharmacy. Other recognitions include the Prince of Asturias Prize, the BBVA Frontiers Prize, the Passano Prize, the Vilcek Prize, the Pasarow Prize in Cancer Research, Spain’s National Prize for Research, the Brupbacher Prize for Cancer Research, the Pezcoller-American Association for Cancer Research International Award, and the International Catalonia Prize. Title of Dr. Massague's Lecture for the Symposium: Latency, immune evasion and outbreak of metastasis initiating cells.

Jonathan Sleeman

Jonathan Sleeman

Jonathan Sleeman studied Natural Sciences at Trinity College, Cambridge, UK, and received his PhD in 1992 from the University of Cambridge. He subsequently received an EMBO Long Term Fellowship and a Marie Curie Stipendium from the European Union to support postdoctoral work at the Forschungszentrum Karlsruhe (now Karlsruhe Institute of Technology (KIT)), Germany. He was appointed Group Leader at the Institute for Toxicology and Genetics (ITG), FZK in 1997 and deputy director of ITG in 2003. Dr. Sleeman was acting Chair of Genetics at the University of Karlsruhe, Germany from 2004-2007. He took up the position of Professor of Microvascular Biology and Pathobiology at the University of Heidelberg, Germany, in January 2008, and has laboratories at KIT and the Medical Faculty Mannheim. Dr Sleeman’s research aims to understand the cellular and molecular regulation of metastasis and to use this knowledge to develop novel anti-cancer therapies.

Michael Speicher

Michael Speicher

Michael R. Speicher, M.D. is Professor of Human Genetics and Head of the Institute of Human Genetics at the Medical University of Graz in Austria. Dr. Speicher studied computer science at the University of Dortmund (Germany) and graduated with an MD degree from the University of Essen (Germany). He conducted his clinical and scientific training in Human Genetics at the University of Heidelberg (Germany), at Yale University (New Haven, USA), and at the University of Munich (Germany). For many years Dr. Speicher studied chromosome structure and morphology using various molecular cytogenetic approaches and mechanisms of chromosomal instability. His more recent research is focused on hereditary tumor syndromes, the contribution of germline and somatic genomic variants to cancer, and single cell analysis. Current research projects are directed towards methods for the non-invasive monitoring of cancer evolution by analyses of circulating tumor cells and circulating tumor DNA.

Wolfgang Janni

Wolfgang Janni

Wolfgang Janni, MD, PhD, is currently a full professor and director in the Department of Obstetrics and Gynecology at the University of Ulm in Germany. He was appointed to this position in October 2012 after working as a full professor and director of the Department of Obstetrics and Gynecology at the Heinrich-Heine-University in Duesseldorf, Germany, from 2008 until 2012. He received the credentials for professorship at Munich University in 2015, but decided to stay in Ulm. In 2016, he was appointed as chair of the German Guideline Council for Breast Cancer (AGO). His two main areas of research include the relevance of liquid biopsy in patients with breast cancer and clinical research. His research has received numerous international awards. He is author or co-author of 213 publications in peer-reviewed journals, including the New England Journal of Medicine, Journal of Clinical Oncology, and Cancer.

Congress date : May 3-5 2018

Organizing committee

Catherine Alix-Panabières
Klaus Pantel

Download Programme

Programme

Important
Dates

  • 15th December 2017
    End of the early registration fees
  • 1st February 2018
    Abstract submission deadline
  • 15th March 2018
    Notification of abstract acceptance & Travel awards
  • 15th April 2018
    End of the standard registration fees
  • 3rd May 2018
    Opening of the ISMRC 2018

Photo
gallery

Montpellier Go to the gallery